A new technology announced by ProScanRxPharma Inc., Grafoid Inc. and Calevia Inc. can selectively search and destroy cancerous prostate cells and destroy them with a flash of red light combining biotechnology and advanced graphene technologies to provide ground-breaking new medical technology.
Reaching this level of innovation requires massive mastery of several fields of science, an effort with massive commercial applications. This is about finding the Holy Grail of cancer therapy: destroying cancer cells without difficult surgery that may or may not eliminate all the cancerous cells, or death defying chemotherapy. For many years now, researchers have been looking at ways to use graphene in cancer therapy by providing a focused way to eliminate cancer cells.
The new technology is rooted in a rudimentary principle that was discovered 100,000 years ago with the discovery of fire: fire burns — and further experimented by every toddler ever since.
Next it is draws on immunology, perhaps one of most misunderstood facet of medicine, by using antibodies that are specific to cancer cells. These antibodies bind to the walls of cancer cells but are rejected by healthy cells. Antibodies are the business end of the immune system that binds to microbes and foreign substances. In carcinogenesis the immune system is unable to produce them to destroy cancer cells. But what if we could arm antibodies with heat guns? Living cells are sensitive to high temperature — fire burns.
The researchers then used the antibodies to coat minuscule amounts of graphene, a single layer of carbon atoms, thus forming a bioconjugate or a biological computer chip. These graphene chips were fabricated for their ability to bind to the non-business end of the antibodies so that when they encounter cancer cells they can bind to their cell walls. This required finding a way to detoxify graphene, a unique process that was developed by Grafoid — graphene oxide is normally toxic to living cells.
This is when things get nasty for cancer cells: when graphene is exposed to near infrared wavelength, it turns it instantly turns it into heat. Near infrared is harmless red light and can’t be felt normally: TV remotes use near infrared waves. Near infrared can also penetrate tissues, hence it can reach tumours that are coated with the antibody-graphene bioconjugate. Again, we know that fire burns. In this case it only burns the cancerous cells.
According to Calevia’s co-founder Dr. Claude Vezeau who serves as President and CEO, further research is needed to calibrate the heat exposure to optimize the tumour removal treatment. In parallel, further research will also add therapies for example breast, kidney, bladder, and bladder cancers. So far these findings have been demonstrated on animal trials. Clinical trials on human subjects are planned within a 2-year horizon.
If these findings can be proven to cure cancer in humans, Calevia might offer us as much a quantum leap in medicine as when Sir Alexander Fleming and co-workers developed the antibiotic substance penicillin from the fungus Penicillium notatum in 1928. Fleming took medicine to a completely new level and triggered the pharmaceutical industry as we know it today.